finance-301-module-5-slp - FINANCE 301- EXTENTED COURSE...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
FINANCE 301- EXTENTED COURSE MODULE 5 – SLP DR. STEPHEN POLLARD Accentia Biopharmaceuticals Inc. said it has acquired the rights to a treatment in the late stages of development that is designed to help people with autoimmune diseases, including multiple sclerosis. The plan for Accentia is to issue stock once the treatment is approved. They are raising approximately $20 million in cash through a financial agreement with several investors. The cash will be raised by issuing convertibles (bonds or preferred stocks that can be converted into common stock) for supporting late drug development programs. Accentia sublicensed the technology from Revimmune and will pay royalties on net sales and forgo 800,000 shares to Revimmune at $8 a share. This type of funding gives investors partial control of the company which could be beneficial to Accentia and extremely risky for investors. Also, they are using other people money to fund this project. This put the burden on the investors who has some belief that
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 10/26/2011 for the course FIN 301 taught by Professor Dr.sopko during the Fall '11 term at Trident Technical College.

Page1 / 3

finance-301-module-5-slp - FINANCE 301- EXTENTED COURSE...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online